Jean-Paul Kress
Chief Executive Officer presso MORPHOSYS AG
Patrimonio netto: - $ in data 31/03/2024
Profilo
Jean-Paul Kress is currently the CEO & Chairman-Management Board at MorphoSys AG since 2019 and the President & Director at Syntimmune, Inc. since 2018.
Previously, he served as the President & Chief Executive Officer at Sanofi Pasteur MSD SNC from 2011 to 2015.
He was also the Chairman at ERYTech Pharma SA from 2019 to 2023.
In addition, he held positions as an Independent Director at Sarepta Therapeutics, Inc. from 2015 to 2017, Director at Quantum Genomics SA from 2018 to 2019, President-International & Executive Vice President at Biogen, Inc. from 2017 to 2018, and Senior Vice President & Head-North America at Genzyme Corp.
from 2015 to 2017.
Dr. Kress obtained his undergraduate and graduate degrees from École Normale Supérieure in 1991 and his doctorate degree from Faculté De Médecine Necker Enfants Malades Université in 1991.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 31/12/2022 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Jean-Paul Kress
| Società | Posizione | Inizio |
|---|---|---|
| MORPHOSYS AG | Chief Executive Officer | 01/09/2019 |
Syntimmune, Inc.
 Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | President | 03/01/2018 |
Precedenti posizioni note di Jean-Paul Kress
| Società | Posizione | Fine |
|---|---|---|
ERYTech Pharma SA
 ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Chairman | 23/06/2023 |
| QUANTUM GENOMICS | Director/Board Member | 24/06/2019 |
| BIOGEN INC. | Corporate Officer/Principal | 01/01/2018 |
| SAREPTA THERAPEUTICS, INC. | Director/Board Member | 06/06/2017 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/06/2017 |
Formazione di Jean-Paul Kress
| École Normale Supérieure | Graduate Degree |
| Faculté De Médecine Necker Enfants Malades Université | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| BIOGEN INC. | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| MORPHOSYS AG | Health Technology |
| QUANTUM GENOMICS | Health Technology |
| Aziende private | 4 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
ERYTech Pharma SA
ERYTech Pharma SA Pharmaceuticals: MajorHealth Technology ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The firm conducts research and development of innovative red blood cell-based therapeutics for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France. | Health Technology |
Sanofi Pasteur MSD SNC
 Sanofi Pasteur MSD SNC Pharmaceuticals: MajorHealth Technology Sanofi Pasteur MSD SNC is engaged in the wholesale of pharmaceutical products. The company was founded on August 16, 1993 and is headquartered in Lyon, France. | Health Technology |
- Borsa valori
- Insiders
- Jean-Paul Kress
